How much of a roll can pharmaceutical manufacturers play in the social determinants of health? Industry experts, Maureen Hennessey, PhD, and Dominic Galante, MD, discuss how much they can stand to gain in medication adherence and outcomes from partnering with other industry stakeholders and programs around the issue.
Read the full article below.
There’s a simple reason why co-pay accumulators captured the industry’s attention when they rolled out in 2017: Healthcare is too damn expensive and co-pay accelerators, at least in theory, offered a financial workaround.
Read the full article here.
What are the biggest key takeaways from 2019? In the latest All Access newsletter by Precision for Value we asked our advisors to reflect on the market events for the year by type of payer. Get your complimentary copy here.
Gene therapy has sparked significant interest across the health care industry because it offers the tantalizing possibility of a cure. While gene therapy holds great promise, this field of research is still in its nascent stages, and the optimal methods and solutions for unlocking its full clinical potential are still being defined.
Recent years have brought significant innovation in potentially curative therapies for several diseases. By 2025, the FDA anticipates approving 10 to 20 cell and gene therapy products per year, many of which are intended to be one-time curative treatments.
In the latest edition of IPSOR’s Value in Health, Ross Maclean takes an in depth look at several novel measures of value beyond QALY and how they may apply to European health technology assessment.
Can the tools we use to measure value keep up with the pace at which oncology is advancing? Explore how four different frameworks have evolved over time and the role they play in oncology value assessment.
Read the full article here.
Perhaps we should take a closer look at how Apple devices and other internet of things (IoT) technologies are impacting the healthcare landscape and have the potential to impact the standard of care (SOC) in many disease states in the future.
Read the full article here.
A focus on value-based care and other market drivers have led to the development of trendsetters, entrants and disruptors (TEDs). Precision for Value’s Dr. Oyekan and Jorge Font, discuss the five main archetypes of TEDs.
Read the full article here.
Precision medicine is a potential game-changer and oncology expert Jeremy Schafer offers four ways that he believes precision medicine will change cancer treatment.
Read the full article here.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
